EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts-Reference-Cited by-同舟云学术

EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts

Published:2018 Issue:10 Volume:41 Page:634-642
ISSN:2296-5270
Container-title:Oncology Research and Treatment
language:en
Short-container-title:Oncol Res Treat

Author:

Lavdovskaia Elena D.,Iyevleva Aglaya G.,Sokolenko Anna P.,Mitiushkina Natalia V.,Preobrazhenskaya Elena V.,Tiurin Vladislav I.,Ivantsov Alexandr O.,Bizin Ilya V.,Stelmakh Liliya V.,Moiseyenko Fedor V.,Karaseva Nina A.,Orlov Sergey V.,Moiseyenko Vladimir M.,Korzhenevskaya Marina A.,Zaitsev Ivan A.,Kozak Andrey R.,Chistyakov Ivan V.,Akopov Andrey L.,Volkov Nikita M.,Togo Alexandr V.,Imyanitov Evgeny N.

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology

Reference49 articles.

1. Russo A, Franchina T, Ricciardi GR, et al.: A decade of EGFR inhibition in EGFR-mutated non-small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget 2015;6:26814-26825.

2. Piotrowska Z, Sequist LV: Epidermal growth factor receptor-mutant lung cancer: New drugs, new resistance mechanisms, and future treatment options. Cancer J 2015;21:371-377.

3. Pao W, Miller VA, Politi KA, et al.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.

4. Yun CH, Mengwasser KE, Toms AV, et al.: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-2075.

5. Chen HJ, Mok TS, Chen ZH, et al.: Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res 2009;15:651-658.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status of molecular diagnostics for lung cancer;Exploration of Targeted Anti-tumor Therapy;2024-06-27

2. Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes;BMC Medicine;2023-02-24

3. Hereditary cancer syndromes;World Journal of Clinical Oncology;2023-02-24

4. Systematic detection of mosaicism by using digital NGS reveals three new MEN1 mosaicisms;Endocrine Connections;2022-11-01

5. Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer;International Journal of Clinical Oncology;2022-02-16